Zafirlr

Zafirlr is not a recognized pharmaceutical agent in major medical references or regulatory databases. The name does not correspond to an approved drug, active ingredient, or widely catalogued compound. It may be a typographical error for zafirlukast or a fictional or experimental designation used in nonclinical contexts.

If the intended term is zafirlukast, it is a leukotriene receptor antagonist used in the management of asthma. Zafirlukast works by blocking the CysLT1 receptor, reducing the effects of leukotrienes that contribute to bronchoconstriction, inflammation, and mucus production in the airways. It is taken orally and is typically used as part of a long-term treatment plan for mild to moderate persistent asthma in adults and children aged five years and older. It is not a rescue medication and should be used regularly as prescribed.

Pharmacokinetics and safety considerations are characterized by hepatic metabolism and potential drug interactions. Adverse effects commonly reported include abdominal pain, nausea, diarrhea, and headaches. Liver function abnormalities and, rarely, serious hepatic injury have been described, so monitoring may be advised for some patients. Drug interactions may occur with other hepatic enzyme substrates, and adjustments may be needed when coadministered with certain medications such as theophylline or warfarin, depending on the clinical context.

In summary, zafirlukast is a well-established reference drug in asthma management, while zafirlr remains unconfirmed as a recognized agent. If you meant a different name or have a specific context, please provide additional details for a precise entry.